116 related articles for article (PubMed ID: 25656881)
61. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial.
Modest DP; Laubender RP; Stintzing S; Giessen C; Schulz C; Haas M; Mansmann U; Heinemann V
Acta Oncol; 2013 Jun; 52(5):956-62. PubMed ID: 23244709
[TBL] [Abstract][Full Text] [Related]
62. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
Hong DS; Morris VK; El Osta B; Sorokin AV; Janku F; Fu S; Overman MJ; Piha-Paul S; Subbiah V; Kee B; Tsimberidou AM; Fogelman D; Bellido J; Shureiqi I; Huang H; Atkins J; Tarcic G; Sommer N; Lanman R; Meric-Bernstam F; Kopetz S
Cancer Discov; 2016 Dec; 6(12):1352-1365. PubMed ID: 27729313
[TBL] [Abstract][Full Text] [Related]
63. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
Malik Z; Eng C
Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
[No Abstract] [Full Text] [Related]
64. Treatment of metastatic colon cancer: "the times they are A-changing".
Kemeny NE
J Clin Oncol; 2013 Jun; 31(16):1913-6. PubMed ID: 23630214
[No Abstract] [Full Text] [Related]
65. Cetuximab for metastatic colorectal cancer.
Bria E; Cuppone F; Di Maio M
N Engl J Med; 2009 Jul; 361(1):95-6; author reply 96-7. PubMed ID: 19579280
[No Abstract] [Full Text] [Related]
66. Methods of overcoming treatment resistance in colorectal cancer.
Temraz S; Mukherji D; Alameddine R; Shamseddine A
Crit Rev Oncol Hematol; 2014 Feb; 89(2):217-30. PubMed ID: 24075059
[TBL] [Abstract][Full Text] [Related]
67. Multiple pigmented nevi induced by the combination of encorafenib and cetuximab in a colon cancer patient.
Omori R; Miyagaki T; Miyano K; Hashimoto Y; Kadono T
J Dermatol; 2022 Aug; 49(8):e264-e265. PubMed ID: 35403284
[No Abstract] [Full Text] [Related]
68. Fewer cetuximab-related skin-toxicities in colorectal cancer patients treated with encorafenib: a Yin and Yang effect of ERK paradoxical activation.
Ciccolini J; Milano G
Ann Oncol; 2022 Sep; 33(9):981-982. PubMed ID: 35718337
[No Abstract] [Full Text] [Related]
69. Mutations linked to chemotherapy resistance in colorectal cancer.
Fyfe I
Nat Rev Gastroenterol Hepatol; 2023 May; 20(5):269. PubMed ID: 37012321
[No Abstract] [Full Text] [Related]
70. What evidence is there for the reimbursement of personalised medicine?
Hall PS; McCabe C
Pharmacoeconomics; 2013 Mar; 31(3):181-3. PubMed ID: 23436473
[No Abstract] [Full Text] [Related]
71. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response.
Liu X; George GC; Tsimberidou AM; Naing A; Wheler JJ; Kopetz S; Fu S; Piha-Paul SA; Eng C; Falchook GS; Janku F; Garrett C; Karp D; Kurzrock R; Zinner R; Raghav K; Subbiah V; Hess K; Meric-Bernstam F; Hong DS; Overman MJ
BMC Cancer; 2015 Oct; 15():713. PubMed ID: 26474549
[TBL] [Abstract][Full Text] [Related]
72. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
[TBL] [Abstract][Full Text] [Related]
73. External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer.
Tack V; Ligtenberg MJ; Tembuyser L; Normanno N; Vander Borght S; Han van Krieken J; Dequeker EM
Oncologist; 2015 Mar; 20(3):257-62. PubMed ID: 25657200
[TBL] [Abstract][Full Text] [Related]
74. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Joshi M; Rice SJ; Liu X; Miller B; Belani CP
PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
[TBL] [Abstract][Full Text] [Related]
75. Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel.
Thang ND; Nghia PT; Kumasaka MY; Yajima I; Kato M
Asian Pac J Cancer Prev; 2015; 16(2):699-705. PubMed ID: 25684511
[TBL] [Abstract][Full Text] [Related]
76. Molecular pathology of colorectal cancer.
Bosman F; Yan P
Pol J Pathol; 2014 Dec; 65(4):257-66. PubMed ID: 25693079
[TBL] [Abstract][Full Text] [Related]
77. Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.
Foltran L; De Maglio G; Pella N; Ermacora P; Aprile G; Masiero E; Giovannoni M; Iaiza E; Cardellino GG; Lutrino SE; Mazzer M; Giangreco M; Pisa FE; Pizzolitto S; Fasola G
Future Oncol; 2015; 11(4):629-40. PubMed ID: 25686118
[TBL] [Abstract][Full Text] [Related]
78. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
Liang Y; Wakelee HA; Neal JW
Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
[TBL] [Abstract][Full Text] [Related]
79. Clinical implications of intestinal stem cell markers in colorectal cancer.
Espersen ML; Olsen J; Linnemann D; Høgdall E; Troelsen JT
Clin Colorectal Cancer; 2015 Jun; 14(2):63-71. PubMed ID: 25657049
[TBL] [Abstract][Full Text] [Related]
80. The use of combinations of monoclonal antibodies in clinical oncology.
Henricks LM; Schellens JH; Huitema AD; Beijnen JH
Cancer Treat Rev; 2015 Dec; 41(10):859-67. PubMed ID: 26547132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
